238 related articles for article (PubMed ID: 16716800)
1. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Thigpen T
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S26-32. PubMed ID: 16716800
[TBL] [Abstract][Full Text] [Related]
2. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
3. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
4. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
5. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
6. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
7. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Li C; Sun Y; Pan Y; Wang Q; Yang S; Chen H
Lung; 2010 Oct; 188(5):359-64. PubMed ID: 20703493
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A; Herrstedt J; Hardy-Bessard AC; Müller HH; Harter P; Kristensen G; Joly F; Huober J; Avall-Lundqvist E; Weber B; Kurzeder C; Jelic S; Pujade-Lauraine E; Burges A; Pfisterer J; Gropp M; Staehle A; Wimberger P; Jackisch C; Sehouli J
J Clin Oncol; 2010 Sep; 28(27):4162-9. PubMed ID: 20733132
[TBL] [Abstract][Full Text] [Related]
10. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Hansen SW
Semin Oncol; 2002 Feb; 29(1 Suppl 1):17-9. PubMed ID: 11840416
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
16. Optimizing gemcitabine regimens in ovarian cancer.
Pecorelli S; Pasinetti B; Tisi G; Odicino F
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S17-25. PubMed ID: 16716799
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
18. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
19. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Kose MF; Meydanli MM; Tulunay G
Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
